Pegylated liposomal doxorubicin (PLD) is usually used in disseminated HIV-related Kaposi's sarcoma (KS). It is the first-line treatment or second-line therapy in patients who do not tolerate or do not respond to polychemotherapy since 1995, when it was approved by the FDA. We report two cases of disseminated classic KS not associated with immunosuppression in which HHV-8 infection was demonstrated. They showed an excellent response to PLD, with good tolerance and an absence of side effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546630600919993 | DOI Listing |
Publication Analysis
Top Keywords
disseminated classic
8
kaposi's sarcoma
8
excellent response
8
pegylated liposomal
8
liposomal doxorubicin
8
classic kaposi's
4
sarcoma cases
4
cases excellent
4
response pegylated
4
doxorubicin pegylated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!